We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Gene-Disease Link May Help Diagnose Rare Neurodevelopmental Disorders

By LabMedica International staff writers
Posted on 07 Sep 2026

Neurodevelopmental disorders comprise a heterogeneous group of conditions that often emerge early in life and can be difficult to diagnose. Families may face prolonged searches for answers when the underlying genetic cause has not yet been linked to a defined syndrome. Establishing clear gene-disease relationships can reduce uncertainty and guide clinical evaluation. New findings now identify a previously unrecognized genetic form of neurodevelopmental disorder.

University of Otago (Dunedin, New Zealand) researchers identified ELAVL2 variants as the cause of a previously undefined neurodevelopmental disorder and delineated its clinical features. The work, published in The American Journal of Human Genetics, classifies an ELAVL2-related neurodevelopmental disorder characterized by prominent cognitive, behavioral, and neurological features. The study involved an international collaboration between teams at Otago and in the Netherlands.


Image Credit: Adobe Stock
Image Credit: Adobe Stock

Investigators used international gene databases to assemble individuals worldwide who harbored ELAVL2 alterations and shared clinical presentations, including developmental delay and intellectual disability. Functional analyses showed that some variants change the gene’s biological activity, consistent with ELAVL2 haploinsufficiency underlying the disorder. By linking genotype with phenotype, the team established ELAVL2 as a disease gene and formalized the entity as an ELAVL2-related neurodevelopmental disorder.

According to the study authors, the work has already provided answers for 15 individuals and families who participated in the research. The discovery offers a structured basis for case recognition and variant interpretation in clinical genetics. The researchers indicate that ongoing investigations are examining additional members of the ELAVL gene family for similar roles in neurodevelopment and disease.

“Neurodevelopment depends on precise orchestration of the dosage, location and timing of gene expression. Before the study, the gene ELAVL2 was known to have an important role in helping influence brain development, but no one had connected it with a genetic condition. We have now discovered variants in this gene are the cause of a previously undefined neurodevelopmental disorder. The work has helped provide answers for 15 individuals and families who were part of the research and has the potential to help many more,” said Dr. Meghan Mulligan, of the Department of Biochemistry.

“Our discovery not only helps those whānau involved in the study—who now have an answer as to the cause of their family member's neurological condition—but also opens up a new diagnostic pathway for other families with rare and previously unexplained neurodevelopmental disorders. Diagnostic labs globally will be able to use our findings to help other families searching for an answer and potentially receive a genetic diagnosis in a much shorter time frame,” added Mulligan.

Related Links
University of Otago


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.

Latest BioResearch News

New Immune Target Could Support More Precise High Blood Pressure Treatment
07 Sep 2026  |   BioResearch

Researchers Identify Shared Molecular Networks Behind Fatigue-Related Illnesses
07 Sep 2026  |   BioResearch

Blood Metabolite Signature Predicts ALS Progression and Points to Treatment Strategy
07 Sep 2026  |   BioResearch